A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07502027 · clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
55
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Huazhong University of Science and Technology